This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: The University of Texas System. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: The Innovations of Erik Rytting
Introduction
Erik Rytting is an accomplished inventor based in Austin, TX. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents. His work focuses on the modulation of specific biological pathways that are crucial for addressing various human diseases.
Latest Patents
Rytting holds a patent for "Inhibitors of bromodomain-containing protein 4 (BRD4)." This patent describes small molecule selective inhibitors of the BRD4 bromodomain. The compounds outlined in this patent can modulate the bronchiolar NFkB-BRD4 axis, which plays a vital role in the acute neutrophilic response to viral molecular patterns. These compounds have the potential to be developed as preventive and therapeutic agents for a range of human diseases and conditions.
Career Highlights
Erik Rytting is affiliated with the University of Texas System, where he continues to advance his research and innovation. His work has garnered attention for its potential impact on medical treatments and understanding of disease mechanisms.
Collaborations
Rytting collaborates with notable colleagues, including Jia Zhou and Allan R Brasier, who contribute to his research endeavors and enhance the scope of his work.
Conclusion
Erik Rytting's innovative contributions to the field of biomedical research exemplify the importance of developing new therapeutic agents. His patent on BRD4 inhibitors highlights the potential for significant advancements in treating human diseases.